Somatrem

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Somatrem is a drug catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 1 molecular target, including GHR. Recorded indications include Growth retardation and Pituitary dwarfism.

• Molecular targets: GHR (1 listed in DrugCentral).
• Indications: Growth retardation and Pituitary dwarfism.
• ATC code: H01AC02 (Somatropin and somatropin agonists).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Growth retardation
• Pituitary dwarfism

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Growth hormone receptor	GHR	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-10-17	FDA	—	GENENTECH

ATC classification

ATC code	Therapeutic hierarchy
H01AC02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES › Somatropin and somatropin agonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Clear cell renal cell carcinoma	308.8
Lymphoproliferative disorder	268.8
Renal cell carcinoma	98.8
Growth retardation	82.9

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 82030-87-3
• InChIKey: —
• PubChem CID: 5487805

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Somatrem used for?

DrugCentral lists the following indications for Somatrem: Growth retardation and Pituitary dwarfism.

How does Somatrem work?

Its molecular targets in DrugCentral include GHR (agonist).

When was Somatrem first approved?

Somatrem was first approved by the FDA in 1985.

Sources

• DrugCentral drug card 5042 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201620 — compound record and bioactivity
• PubChem CID 5487805 — chemical identifiers
• DrugBank DB09098 — drug record
• FDA UNII CU8D464EDW — substance identity
• DailyMed: FDA labels for Somatrem — current prescribing information (label search)
• UniProt P10912 (GHR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.